Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 7 points (0.0%) at 16,149 as of Thursday, Oct. 16, 2014, 1:15 PM ET. The NYSE advances/declines ratio sits at 2,140 issues advancing vs. 904 declining with 135 unchanged.

The Drugs industry currently sits up 1.3% versus the S&P 500, which is up 0.1%. A company within the industry that increased today was Teva Pharmaceutical Industries ( TEVA), up 2.6%. On the negative front, top decliners within the industry include Novartis ( NVS), down 1.6%, Merck ( MRK), down 1.6%, Novo Nordisk A/S ( NVO), down 1.4%, Sanofi ( SNY), down 1.5% and AstraZeneca ( AZN), down 0.7%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Grifols ( GRFS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Grifols is up $1.40 (4.7%) to $31.40 on heavy volume. Thus far, 716,817 shares of Grifols exchanged hands as compared to its average daily volume of 753,400 shares. The stock has ranged in price between $29.65-$31.40 after having opened the day at $29.65 as compared to the previous trading day's close of $30.00.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $10.3 billion and is part of the health care sector. Shares are down 16.9% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate Grifols a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, impressive record of earnings per share growth and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Illumina ( ILMN) is up $6.79 (4.4%) to $160.38 on heavy volume. Thus far, 1.0 million shares of Illumina exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $152.80-$160.59 after having opened the day at $154.72 as compared to the previous trading day's close of $153.59.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $20.8 billion and is part of the health care sector. Shares are up 34.8% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Shire ( SHPG) is up $6.67 (3.9%) to $177.16 on heavy volume. Thus far, 7.1 million shares of Shire exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $172.59-$180.42 after having opened the day at $173.50 as compared to the previous trading day's close of $170.49.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $48.1 billion and is part of the health care sector. Shares are up 73.1% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Shire a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and notable return on equity. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Shire Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null